Patrick G. Enright, MBA
Managing Director, Longitude Capital

Mr. Enright is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately-held and publicly-traded biotechnology companies, such as SUGEN, Inc. and Cephalon, Inc. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience. He was CFO and Senior Vice President Business Development of Valentis, Inc. (NASDAQ: VLTS) and Senior Vice President Finance and Business Development of Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche). Mr. Enright began his life sciences career 23 years ago at Sandoz (now Novartis). He currently serves on the boards of Threshold Pharmaceuticals (NASDAQ: THLD), Sequenom (NASDAQ: SQNM), DiObex, Codexis, Horizon Therapeutics, MAP Pharmaceuticals, Prestwick Pharmaceuticals, Raven biotechnologies and InfaCare Pharmaceuticals. Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.